SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- Somaxon Pharmaceuticals, Inc., today announced that Kenneth Cohen, President and Chief Executive Officer, will present a company update at the 24th Annual JPMorgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2006 at 10:00 a.m. PST.
Interested parties will be able to listen to a live webcast of the presentation by visiting www.somaxon.com and connecting via a link to the JPMorgan website at http://equityconferences.jpmorgan.com. Visitors should select the JPMorgan Healthcare Conference link and register. A replay of the webcast will be archived until Thursday, January 26, 2006.
About Somaxon Pharmaceuticals
Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon’s lead product, SILENOR(TM), is in Phase III clinical trials for the treatment of insomnia.
Contact: Investors please contact Meg McGilley, CFO (858.509.3670), or Rob Whetsone, Pondel/Wilkenson, Inc. (310.279.5980). Media please contact Jeff Raser, Sr. VP. (858.509.3670).
Somaxon Pharmaceuticals, Inc.
CONTACT: Investors, Meg McGilley, CFO, or Media, Jeff Raser, Sr. VP., bothof Somaxon Pharmaceuticals, Inc., +1-858-509-3670; or Investors, RobWhetsone of Pondel/Wilkenson, Inc., +1-310-279-5980, for SomaxonPharmaceuticals, Inc.
